Journal
MICROBIOLOGY AND IMMUNOLOGY
Volume 53, Issue 10, Pages 567-572Publisher
WILEY
DOI: 10.1111/j.1348-0421.2009.00160.x
Keywords
antibody treatment; antiviral therapy; viral infection
Categories
Funding
- Barndiabetesfonden
- Swedish Diabetes Association
- Karolinska Institutet
- Swedish Research Council
- Swedish Society for Medical Research
- Novo Nordisk Foundation
- Family Erling-Persson Foundation
- Swedish Diabetes Foundation
- TONECA, Eurodia [FP6-518153]
- Juvenile Diabetes Research Foundation International
Ask authors/readers for more resources
The effects of LV in two different species, CD-1 mice, without a genetic disposition for diabetes, and BB rats prone to T1D were examined. Male CD-1 mice that had been exposed to LV in utero developed a type 2-like diabetes with increased blood glucose, insulin levels and epididymal fat at the age of 10-15 weeks. Combination therapy including LV-antiserum and an antiviral drug, Pleconaril, significantly reduced the levels of blood glucose and insulin and the amount of abdominal fat. In BB rats, LV has been found in both prediabetic- and diabetic diabetes-prone rats, as well as in diabetes-resistant rats. To evaluate whether the presence of LV has any influence on the onset of T1D, prediabetic BB rats were treated with an antiserum against LV or a combination of the antiviral drugs Pleconaril and Ribavirin. In the group treated with antiviral drugs, the onset was significantly delayed. These results indicate that the presence of LV can be involved in the pathogenesis of diabetes in these animal models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available